Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple pill prevent pancreatitis after ERCP? new study tests two drugs

NCT ID NCT06252441

Prevention Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether taking oral N-Acetyl cysteine before an ERCP procedure could prevent pancreatitis as well as the standard treatment, rectal diclofenac. Forty-six adults at risk for pancreatitis after ERCP received one of the two drugs. The goal was to see which drug better reduces inflammation and prevents pancreatitis from developing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
N-Acetyl cysteine and diclofenac
What this could lead to
If it works, this could point toward a safer or more effective way to prevent pancreatitis after ERCP.
What could go wrong
This is a small, early-phase study with only 46 participants, so results may not apply to everyone. The drugs may not work as hoped or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

46 people

The number who actually took part.

Started

Mar 2024

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age more than 18 years old. 2. Gender: males and females. 3. Patients with suitable indications for ERCP due to suspected pancreato-biliary disorders. 4. Blood amylase and lipase levels before ERCP are within the normal limits. Exclusion Criteria: 1. Age of less than 18 years old. 2. Uncontrolled diabetes mellitus (DM). 3. Severe bleeding tendency. 4. Impaired renal function (serum creatinine \> 2 mg/dL), (creatinine clearance \<30 ml/min). 5. Patients with severe heart disease. 6. Currently pregnant or nursing. 7. Admission due to established pancreatitis before ECRP. 8. Unwillingness to undergo ERCP. 9. Previously documented allergy to NAC or diclofenac or any other NSAIDs. 10. History of NSAIDs intake one week before the procedure. 11. Recent Active bleeding, ulcer, or asthma. 12. Patients with rectal disease (hemorrhoids, fissures, abscesses, and incontinence).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post-ercp pancreatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute pancreatitis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Post-ercp pancreatitis

Contacts and locations

Locations

  • Obstructive Jaundice Clinic in the National Liver Institute, Menoufia University , Shebin Elkoom

    Menofia, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.